News - Anti-virals

Filter

Current filters:

Anti-virals

Popular Filters

376 to 400 of 416 results

Indian HIV drugs market forecast to reach $54 million by 2014

23-11-2011

The market for HIV drugs in India is expected to reach 454 million by 2014, according to a new report…

Anti-viralsAsia-PacificGenericsMarkets & MarketingPharmaceutical

Gilead expands hepatitis C R&D portfolio with $11 billion buy of Pharmasset

22-11-2011

In its biggest M&D deal to date, Gilead Sciences (Nasdaq: GILD) says it has signed a definitive agreement…

Anti-viralsBiotechnologyGilead SciencesMergers & AcquisitionsmericitabinePharmaceuticalPharmasset

Hepatitis C drug market in Mexico expected to double to $104 million in 2015

21-11-2011

The hepatitis C virus (HCV) market in Mexico will nearly double from $56 million in 2010 to $104 million…

Anti-viralsIncivekMarkets & MarketingMerck & CoPharmaceuticalRocheSouth AmericaVertexVictrelis

Gilead in another licensing deal with J&J unit for combo HIV/AIDS treatment

16-11-2011

US biotech firm Gilead Sciences (Nasdaq: GILD) has entered into a license agreement with Tibotec Pharmaceuticals,…

Anti-viralsBiotechnologycobicistatEmtrivaGilead SciencesJohnson & JohnsonLicensingPharmaceuticalPrezistaResearchTibotec

Kenya gets $345 million from Global Fund for HIV/AIDS fight

14-11-2011

Over the next few weeks, Kenya will be signing a $345 million grant agreement with the Global Fund to…

Anti-viralsFinancialHealthcarePharmaceuticalRest of the World

Novartis’ alisporivir may become first interferon-free oral for hepatitis C G2/G3

14-11-2011

The clear conclusion from a clinical trial of alisporivir (DEB025, from Swiss drug major Novartis [NOVN:…

alisporivirAnti-viralsDebiopharmNovartisPharmaceuticalResearch

Public health groups launch global campaign against Abbott Labs’ monopoly on critical AIDS medicine

11-11-2011

A global campaign to challenge US health care major Abbott Laboratories’ (NYSE: ABT) monopolistic…

Abbott LaboratoriesAnti-viralsGenericsGlobalKaletra CapsulesPharmaceuticalPricing

Hepatitis B vaccines market forecast to show moderate growth until 2018

03-11-2011

The global hepatitis B vaccines market is estimated to be worth $997.0 million in 2010, and is forecast…

Anti-viralsGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalVaccines

Bristol-Myers in licensing deal with Gilead for combination HIV pill

26-10-2011

US drug major Bristol-Myers Squibb (NYSE: BMY) has entered into a licensing accord with biotech firm…

Anti-viralsBiotechnologyBristol-Myers SquibbcobicistatGilead SciencesLicensingPharmaceuticalReyataz

Gilead collaborates with GlobeImmune to develop vaccine for chronic hepatitis B infection

25-10-2011

Gilead Sciences (Nasdaq: GILD) has entered into an exclusive worldwide license and collaboration agreement…

Anti-viralsBiotechnologyGilead SciencesGlobeImmuneLicensingResearchVaccines

Immdal sells Newport to Ewopharma; establishes Immcell

24-10-2011

Privately-held Irish drugmaker Immdal last week announced the sale of its subsidiary Newport Pharmaceuticals…

Anti-viralsEwopharmaImmdalMergers & AcquisitionsNewport PharmaPharmaceutical

Superior combo therapies to sustain HIV/AIDS market growth despite major patent expiries

19-10-2011

The HIV/AIDS therapeutics market is a growing therapy sector, with the USA dominating in terms of revenues.…

Anti-viralsGlobalMarkets & MarketingPatentsPharmaceutical

Roche to boost hep C offerings with $230 million acquisition of Anadys Pharma

18-10-2011

In a further move to broaden in presence outside its current domination in the oncology sector, Swiss…

Anadys PharmaceuticalsAnti-viralsMergers & AcquisitionsPharmaceuticalRoche

Scripps scientists’ findings could advance AIDS vaccine development

16-10-2011

Researchers at the USA-based Scripps Research Institute have uncovered the surprising details of how…

Anti-viralsPharmaceuticalResearchVaccines

ViiV Healthcare announces 16 new grantees for 2011/2012 to prevent mother-to-child HIV transmission

13-10-2011

ViiV Healthcare, the HIV/AIDS joint venture of UK drugs giant GlaxoSmithKline (LSE: GSK) and US behemoth…

Anti-viralsFinancialGlaxoSmithKlineHealthcarePfizerPharmaceuticalRest of the WorldViiV Healthcare

Biotron shares leap 29% on hepatitis C Ph IIa positive results; Inovio advances hepatitis vaccines

11-10-2011

Australian firm Biotron (ASX: BIT) has received some strong support in the first couple of hours of market…

Anti-viralsBiotronInovio PharmaceuticalsLicensingPharmaceuticalResearchVaccinesVGX International

Boehringer license novel HIV non-catalytic integrase inhibitors to Gilead

07-10-2011

Two of the big names in HIV/AIDS drug research and marketing, the USA’s Gilead Sciences (Nasdaq:…

Anti-viralsBoehringer IngelheimGilead SciencesLicensingPharmaceutical

UNAIDS calls for urgent analysis and more research on hormonal contraceptives and HIV infection risk

06-10-2011

The Joint United Nations Programme on HIV/AIDS (UNAIDS) is following with concern data from recent studies…

Anti-viralsGlobalHealthcarePharmaceuticalReproductive

Access to essential HIV/AIDS treatments shows political will as most important factor for success

05-10-2011

Access to antiretroviral therapy (ART) has increased dramatically over the last 10 years, according to…

Anti-viralsGlobalMarkets & MarketingPharmaceuticalPolitics

MVA-B Spanish HIV vaccine shows 90% immune response in humans

28-09-2011

Phase I clinical trials developed by Spanish Superior Scientific Research Council (CSIC) together with…

Anti-viralsPharmaceuticalResearch

PharmAthene awarded 50% profit split on SIGA smallpox drug

25-09-2011

USA-based PharmAthene (NYSE Amex: PIP) last week won a significant decision in its litigation against…

Anti-viralsFinancialLegalNorth AmericaPharmaceuticalPharmAtheneSIGA Technologies

Boehringer once-daily AIDS drug Viramune cleared in EU

21-09-2011

Independent German drug major Boehringer Ingelheim says that once-daily Viramune (nevirapine) prolonged-release…

Anti-viralsBoehringer IngelheimEuropePharmaceuticalRegulationViramune

376 to 400 of 416 results

Back to top